Clinical Trial Update: A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI [Phase 3]

View source ↗

Summary

A Phase 3 trial protocol compares Vorolanib tablets plus Everolimus against Sunitinib in advanced renal cell carcinoma patients who progressed after immunothera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Sunitinib (sunitinib)
• Vorolanib (vorolanib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Renal Cell Carcinoma (RCC) | Phase 3 | Status: NOT_YET_RECRUITING